BioNTech, COVID-19 vaccine
BioNTech plots first wave of cancer launches in 2026 as COVID vaccine sales continue to disappoint
As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. | With plans to have at least 10 potentially registrational trials underway by the end of 2024,
BioNTech Seesaws As Covid Sales Plummet With 90% Of Revenue Still To Come
BioNTech stock seesawed early Monday after Covid vaccine sales dropped again in the first quarter, amid wide losses.
BioNTech's Outlook Gives Vaccine Maker a Shot in the Arm
BioNTech's long-term outlook helped it shrug off a first-quarter loss and sinking revenue as demand for COVID-19 vaccines declined.
BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline
BioNTech (BNTX) on Monday swung to a first-quarter loss as the German drugmaker's revenue tumbled more than expected year-on-year due to lower commercial sales of its COVID-19 vaccine. The company posted a per-share loss of 1.
BioNTech records Q1 net loss, revenue falls on lower COVID vaccine sales
Additionally, BioNTech’s diluted earnings per share dropped from €2.05 in Q1 2023 to a net loss per share of €1.31. Beyond the topline results, BioNTech’s quarterly R&D expenses totaled €507.5 million, up from €334 million in Q1 2023, while its general and administrative expenses increased from €111.8 million to €117 million.
BioNTech Swings to Net Loss on Lower Covid Vaccine Sales
By Helena Smolak BioNTech swung to a net loss in the first quarter on plummeted revenue after a sharp decline in its Covid-19 vaccine sales. The
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.
BioNTech says 90% of 2024 revenues will accrue at end of year
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday ...
Yahoo Finance1h
What's Going With BioNTech Stock On Monday?
Guidance: BioNTech said it is still targeting 2024 revenues of 2.5 billion euros to 3.1 billion euros. Partner Pfizer Inc ...
FiercePharma10d
GSK pulls Pfizer and BioNTech into yet another COVID-19 vaccine patent lawsuit
Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech ...
GSK Sues Pfizer, BioNTech for Share of Billions in Vaccine Sales
GlaxoSmithKline filed a federal lawsuit seeking to recoup a share of the tens of billions of dollars in revenue Pfizer and ...
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial ...
BioSpace10d
GSK Sues Pfizer and BioNTech Over Alleged COVID-19 Patent Infringement
With its lawsuit filed against Pfizer and BioNTech, the British multinational biopharma has joined the high-profile patent ...
Reuters11d
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GSK said in the lawsuit , opens new tab that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the ...